thymosin beta-4 fragment peptide
TB-500 updates
Answer
3 changes for TB-500 in the last 12 months. Latest: 2026-04-16.
| Date | Type | What changed | Source |
|---|---|---|---|
| 2026-04-16 | Action | Ohio Board of Pharmacy: board | Regulator Ohio Board of Pharmacy |
| 2026-04-16 | Federal Register | Federal Register notice: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated | Regulator Federal Register |
| 2026-03-23 | Trial | New trial registered: TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | Trial register ClinicalTrials.gov |
| 2023-06-12 | Warning letter | FDA warning letter to Warrior Labz SARMS: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
From ClinicalTrials.gov, EU CTIS, FDA labels, recalls, shortages and warning letters, the Federal Register, and regulators' published actions. Not medical advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.